Search Results - "Yu, Channing"

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer by Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, Yu, Helena A

“…Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most -mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors…”
Get more information

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines by Yu, Channing, Mannan, Aristotle M, Yvone, Griselda Metta, Ross, Kenneth N, Zhang, Yan-Ling, Marton, Melissa A, Taylor, Bradley R, Crenshaw, Andrew, Gould, Joshua Z, Tamayo, Pablo, Weir, Barbara A, Tsherniak, Aviad, Wong, Bang, Garraway, Levi A, Shamji, Alykhan F, Palmer, Michelle A, Foley, Michael A, Winckler, Wendy, Schreiber, Stuart L, Kung, Andrew L, Golub, Todd R

“…A method called PRISM rapidly identifies drug candidates that are effective against specific cancer cell lines. Hundreds of genetically characterized cell…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Delineation of Tumor Habitats based on Dynamic Contrast Enhanced MRI by Chang, Yu-Cherng Channing, Ackerstaff, Ellen, Tschudi, Yohann, Jimenez, Bryan, Foltz, Warren, Fisher, Carl, Lilge, Lothar, Cho, HyungJoon, Carlin, Sean, Gillies, Robert J., Balagurunathan, Yoganand, Yechieli, Raphael L., Subhawong, Ty, Turkbey, Baris, Pollack, Alan, Stoyanova, Radka

“…Tumor heterogeneity can be elucidated by mapping subregions of the lesion with differential imaging characteristics, called habitats. Dynamic Contrast Enhanced…”
Get full text

Structural mechanism of synergistic activation of Aurora kinase B/C by phosphorylated INCENP by Abdul Azeez, Kamal R., Chatterjee, Sneha, Yu, Channing, Golub, Todd R., Sobott, Frank, Elkins, Jonathan M.

“…Aurora kinases B and C (AURKB/AURKC) are activated by binding to the C-terminal domain of INCENP. Full activation requires phosphorylation of two serine…”
Get full text

A Critical Role for Eosinophils in Allergic Airways Remodeling by Humbles, Alison A., Lloyd, Clare M., McMillan, Sarah J., Friend, Daniel S., Xanthou, Georgina, Erin. E. Mc Kenna, Ghiran, Sorina, Gerard, Norma P., Yu, Channing, Orkin, Stuart H., Gerard, Craig

“…Features of chronic asthma include airway hyperresponsiveness, inflammatory infiltrates, and structural changes in the airways, termed remodeling. The…”
Get full text

Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1 by Orkin, Stuart H, Li, Zhe, Godinho, Frank J, Klusmann, Jan-Henning, Garriga-Canut, Mireia, Yu, Channing

“…Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down…”
Get full text

Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo by Yu, Channing, Cantor, Alan B, Yang, Haidi, Browne, Carol, Wells, Richard A, Fujiwara, Yuko, Orkin, Stuart H

“…Transcription factor GATA-1 reprograms immature myeloid cells to three different hematopoietic lineages-erythroid cells, megakaryocytes, and eosinophils…”
Get full text

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study by Kogawa, Takahiro, Yonemori, Kan, Masuda, Norikazu, Takahashi, Shunji, Takahashi, Masato, Iwase, Hirotaka, Nakayama, Takahiro, Saeki, Toshiaki, Toyama, Tatsuya, Takano, Toshimi, Onuma, Hiroshi, Ogawa, Hayao, Tanaka, Yoshimi, Igari, Yoshiko, Sugihara, Masahiro, Vigliotti, Michele, Yu, Channing, Olivo, Martin Sebastian, Ueno, Suguru, Iwata, Hiroji

“…Abstract only…”
Get full text

X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction by Yu, Channing, Niakan, Kathy K., Matsushita, Mark, Stamatoyannopoulos, George, Orkin, Stuart H., Raskind, Wendy H.

“…Transcription factor GATA-1 is essential for the development of erythroid cells and megakaryocytes. Each of its 2 zinc fingers is critical for normal function…”
Get full text

Performance Assessment in Airway Management Training for Nonanesthesiology Trainees: An Analysis of 4,282 Airway Procedures Performed at a Level-1 Trauma Center by GRISSOM, Thomas E, SAPPENFIELD, Joshua, GALVAGNO, Samuel M, CHERRY, Shane V, CHANNING CHANG, Yu-Cherng, HU, Peter F

“…Although the use of an anesthesiology "airway" rotation to train the nonanesthesiologist is commonly employed, little data exist on the utility, clinical…”
Get full text

PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding by Zhang, Pu, Zhang, Xiaobo, Iwama, Atsushi, Yu, Channing, Smith, Kent A., Mueller, Beatrice U., Narravula, Salaija, Torbett, Bruce E., Orkin, Stuart H., Tenen, Daniel G.

“…The lineage-specific transcription factors GATA-1 and PU.1 can physically interact to inhibit each other's function, but the mechanism of repression of GATA-1…”
Get full text

PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding by Zhang, Pu, Zhang, Xiaobo, Iwama, Atsushi, Yu, Channing, Smith, Kent A., Mueller, Beatrice U., Narravula, Salaija, Torbett, Bruce E., Orkin, Stuart H., Tenen, Daniel G.

“…The lineage-specific transcription factors GATA-1 and PU.1 can physically interact to inhibit each other's function, but the mechanism of repression of GATA-1…”
Get full text

FOG, a Multitype Zinc Finger Protein, Acts as a Cofactor for Transcription Factor GATA-1 in Erythroid and Megakaryocytic Differentiation by Tsang, Alice P, Visvader, Jane E, Turner, C.Alexander, Fujiwara, Yuko, Yu, Channing, Weiss, Mitchell J, Crossley, Merlin, Orkin, Stuart H

“…The hematopoietic transcription factor GATA-1 is essential for development of the erythroid and megakaryocytic lineages. Using the conserved zinc finger…”
Get full text

Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line by Weiss, Mitchell J., Yu, Channing, Orkin, Stuart H.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Real-world treatment patterns and progression-free survival among patients with metastatic castration-resistant prostate cancer: Examining the benefits of sequential androgen receptor pathway inhibitor use by Patel, Jeetvan, Sawhney, Amrita, Byrne, Clare, Tang, Jackson, Yu, Channing

“…64 Background: Numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), but real-world…”
Get full text

Real-world treatment patterns in the U.S. and trends pre-post CARD trial among patients with metastatic castration-resistant prostate cancer by Ghantoji, Shashank, Yu, Channing, Sawhney, Amrita, Byrne, Clare, Tang, Jackson, Runeckles, Kyle, Patel, Jeetvan

“…e17024 Background: Numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC). The…”
Get full text

Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) use by US urologists and oncologists by Nguyen, Jennifer, Patel, Jeetvan, Kang, Barinder, Yu, Channing, Sawhney, Amrita, Fallick, Mark, Gorritz, Magdaliz, Chen, Chi-Chang, Paltanwale, Queenie, Sun, Kainan, Shore, Neal D.

“…e17048 Background: 177 Lu-PSMA-617 was approved by the US Food and Drug Administration in March 2022 for the treatment of patients with prostate-specific…”
Get full text

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours by Serrano, César, Mariño-Enríquez, Adrián, Tao, Derrick L., Ketzer, Julia, Eilers, Grant, Zhu, Meijun, Yu, Channing, Mannan, Aristotle M., Rubin, Brian P., Demetri, George D., Raut, Chandrajit P., Presnell, Ajia, McKinley, Arin, Heinrich, Michael C., Czaplinski, Jeffrey T., Sicinska, Ewa, Bauer, Sebastian, George, Suzanne, Fletcher, Jonathan A.

“…Background Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of…”
Get full text

Genome-scale screens identify factors regulating tumor cell responses to natural killer cells by Sheffer, Michal, Lowry, Emily, Beelen, Nicky, Borah, Minasri, Amara, Suha Naffar-Abu, Mader, Chris C., Roth, Jennifer A., Tsherniak, Aviad, Freeman, Samuel S., Dashevsky, Olga, Gandolfi, Sara, Bender, Samantha, Bryan, Jordan G., Zhu, Cong, Wang, Li, Tariq, Ifrah, Kamath, Govinda M., Simoes, Ricardo De Matos, Dhimolea, Eugen, Yu, Channing, Hu, Yiguo, Dufva, Olli, Giannakis, Marios, Syrgkanis, Vasilis, Fraenkel, Ernest, Golub, Todd, Romee, Rizwan, Mustjoki, Satu, Culhane, Aedin C., Wieten, Lotte, Mitsiades, Constantine S.

“…To systematically define molecular features in human tumor cells that determine their degree of sensitivity to human allogeneic natural killer (NK) cells, we…”
Get full text